October 27, 2015 Approval Letter - IMLYGIC

IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
Source: What's New at CBER - Category: Biomedical Science Source Type: news